Microvessels form the blood-brain barrier, a network that regulates molecular transfer between the vasculature and brain parenchyma. In cerebral small vessel disease (SVD), a leading cause of stroke ...

Amyloid immunotherapies are here, but inflammaging remains a powerful driver of neurodegenerative disease. Neuroinflammation is a rich, but thus far quite elusive, source of new drug targets. Some ...

Common variants in the phosphoinositol phosphatase INPP5D are linked to an increased risk of late-onset Alzheimer’s disease, but no one is quite sure why. Recent work suggests that depleting INPP5D in ...

With two amyloid immunotherapies on the market in many countries, scientists are eager for information on how durable their clinical effects will be. At this year’s Alzheimer’s Association ...

First trial of concurrent amyloid and tau immunotherapies in sporadic Alzheimer’s is underway. Safety data are a go for subcutaneous remternetug. Plaque removal correlates with cognitive benefit in ...

Talk about a closely watched study. Conference after conference, Roche scientists running the ongoing Brain Shuttle AD trial of trontinemab are dispensing morsels of news from sequential interim ...

Cerebrospinal fluid and plasma markers are now being used to help diagnose Alzheimer’s in memory clinics, but what about using them to stage the disease? That’s the next big step, said Henrik ...

Mivelsiran docks APP products in early AD. Phase 2 trial asks: Can it treat CAA? LX1001 gene therapy boosts CSF ApoE2, stabilizes AD biomarkers. Intranasal insulin quells systemic inflammation. These ...

Fewer than 1 percent of amyloid-targeted monoclonal antibodies like lecanemab and donanemab reach their targets in the brain. The excess doses required to make up for this problem raise the risk of ...

A top researcher’s fall from grace sends shock waves through the scientific community. Such is the case with neuropathologist Eliezer Masliah, who stands accused of image falsification spanning 26 ...

Among the hundreds of studies presented at this year’s Alzheimer’s Association International Conference, held July 27 to August 1 in Philadelphia, one of the few that made a splash in the news was not ...